Entered Into The GameLong time coming but we have come off the sidelines and entered the game. The IND filing is a milestone. Congrats to Gail and the Promis Team. The phrases I liked most in the press release about PMN 310 compared to the competition are: the least impacted by monomer competition, a greater toxic oligomer binding level, lack of off target binding to plaque, off target binding is associated with ARIA (which is not what PMN 310 will do), possibility of a more favorable safety profile, potentially differentiated clinical profile compared to other antibody therapeutics in AD-either approved or currently in development. I hear confidence in this press release, saying that PMN 310 is the best hope for an AD therapeutic that could work and provide hope for those who have the disease.